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ABSTRACT
Background and Objectives: Recently, the prognostic value of N-terminal brain natriuretic peptide (NT-proBNP) in acute 
coronary syndrome has been demonstrated in many studies. However, NT-proBNP levels are influenced by various factors 
such as sex, age, renal function, heart failure severity, and obesity. NT-proBNP concentrations tend to decrease with higher 
body mass index (BMI). The aim of this study was to examine the influence of obesity on NT-proBNP as a predictive prog-
nostic factor in acute myocardial infarction (AMI) patients. Subjects and Methods: Using data from the Korea Acute 
Myocardial Infarction Registry (January 2005 to September 2008), 2,736 AMI patients were included in this study. These pa-
tients were divided into men (n=1,972, 70%) and women (n=764, 30%), and were grouped according to their BMIs. Major ad-
verse cardiac events (MACE) during 1 year clinical follow-up were evaluated. Results: NT-proBNP was significantly higher 
in lower BMI (p<0.001). Mean NT-proBNP levels of each obesity group were 2,393±4,022 pg/mL in the lean group (n=875), 
1,506±3,074 pg/mL in the overweight group (n=724) and 1,100±1,137 pg/mL in the obese group (n=1,137) (p<0.01). NT-
proBNP was an independent prognostic factor of AMI in obese patients by multivariative analysis of independent risk fac-
tors of MACE (p=0.01). Conclusion: NT-proBNP is lower in obese AMI patients than in non-obese AMI patients, but NT-
proBNP is still of independent prognostic value in obese AMI patients. (Korean Circ J 2010;40:558-564)
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Introduction
There are many clinical predictors of adverse outcomes af-
ter acute myocardial infarction (AMI). Although various kinds 
of risk scores
1)2) and individual risk factors are already in use 
in clinical practice, many research centers are searching for 
better predictive tools. Recently, the prognostic value of N-
terminal brain natriuretic peptide (NT-proBNP) in acute cor-
onary syndrome (ACS) has been demonstrated in many stu-
dies.
3)4) In one of the largest NT-proBNP studies on ACS, NT-
proBNP had a stronger correlation with mortality than any 
other markers studied, including cardiac troponin T and C-
reactive protein.
4)
NT-proBNP is released from myocardial cells in response 
to volume expansion in heart failure (HF) and is therefore 
used for early diagnosis of symptomatic or asymptomatic 
HF.
5) In addition, NT-proBNP is released in stressed cardiac 
walls in ACS before myocardial necrosis, so the measurement 
of NT-proBNP can provide an early estimate of the risk of 
ACS.
6)7) 
However, a diagnostic NT-proBNP cut-off value in ACS has 
proved difficult to establish as NT-proBNP levels are influ-
enced by various factors including sex, age, renal function, 
HF severity and obesity. The normal values tend to increase 
with age and to be higher in women than in men.
8) NT-pro-
BNP is cleared by the kidney, so its plasma concentration is 
elevated in decreased renal function states.
9) Furthermore, NT-
proBNP levels decrease with higher body mass index (BMI).
10)11)
With the lowering effect of obesity on NT-proBNP levels in 
mind, we investigated the influence of obesity on the prog-
nostic value of NT-proBNP in ACS. 
 
 Subjects and Methods
 
 Patient population and study design
This study included the 2,736 patients with AMIs among 
12,841 patients registered at the Korean Acute Myocardial In-
farction Registry (KAMIR) from January 2005 to September 
2008. The KAMIR is a prospective, multi-center, observational 
registry designed to examine current epidemiology, in-hospi-
tal management, and outcome of patients with AMIs in Ko-
rea for the commemoration of the 50th anniversary of the 
Korean Circulation Society.
12) To focus on NT-proBNP and obe-
sity in AMI patients, we excluded: patients less than 20 or more 
than 90 years of age, patients with previous HF, patients with 
renal insufficiency (elevated serum creatinine level above 2.0 
mg/dL) and missing or uncertain data. This left 2,736 patients 
for final analysis. Major adverse cardiac events (MACE) for one 
year clinical follow-up were evaluated and defined as the com-
posite of 1) cardiac death, 2) non-fatal myocardial infarction 
(MI), 3) re-percutaneous coronary intervention, 4) coronary 
artery bypass graft. We analyzed baseline demographic and 
clinical characteristics, and related laboratory results includ-
ing NT-proBNP (pg/mL) which was measured on arrival. In 
order to investigate the relationship between NT-proBNP and 
MACE, we defined AMI patients free of MACE as group I and 
patients who developed MACE as group II. Each group was 
further divided into men (n=1,972, 70%) and women (n= 
764, 30%), and were grouped as follows based on BMI (kg/m
2) 
in accordance with the World Health Organization (WHO) 
BMI cut-off values for overweight and obesity in Asians
13): 1) 
Lean (BMI ≤22.9 kg/m
2, 2) Overweight (BMI between 23.0 
kg/m
2 and 24.9 kg/m
2), 3) Obese (BMI ≥25.0 kg/m
2). 
 
Statistical analysis
We compared the NT-proBNP levels between patients free 
of MACE (group I) and patients with MACE (group II) dur-
ing 1 year of clinical follow-up among the lean, overweight, 
and obese groups. We used the Statistical Package for the So-
cial Sciences (SPSS) for Windows, version 15.0 (SPSS, Inc., 
Chicago, IL, USA), for analysis. Continuous variables with nor-
mal distributions were expressed as the mean±standard de-
viation and compared with the Student’s t-test. Because NT-
proBNP and the logarithm of NT-proBNP were not normally 
distributed in this study, we used the Mann Whitney U test to 
compare the means of NT-proBNP between groups I and II. 
Categorical variables were compared with the chi-square test, 
where appropriate. Multiple linear regression was used to an-
alyze the strength of association between NT-proBNP and BMI 
after adjusting for age, sex, and renal function. We compared 
the means of NT-proBNP among the obesity groups by Krus-
kal-Wallis test. We finally evaluated the prognostic value of 
NT-proBNP in each obesity group (lean, overweight, obese) 
by binary logistic regression. 
Results
Baseline clinical characteristics of the study 
population
Among the 2,736 AMI patients who were followed-up for 
one year, there were 1,977 male patients (72.4%), 1,703 ST-seg-
ment elevation myocardial infarction patients (62.2%) and 258 
patients with MACE (9.4%). There were 978 (41.6%) obese 
AMI patients. Baseline clinical characteristics and laboratory 
findings of the study population are described in Table 1. Pa-
tients in group II were older (p=0.015), more likely to have di-
abetes mellitus (DM) (p=0.011) and had a higher NT-proB-
NP level (p<0.001) than patients in group I. 
Influencing factors of N-terminal brain natriuretic
peptide
As analyzed by multiple regression (Table 2), significantly 
influencing factors of NT-proBNP were sex, creatinine level, 
creatine kinase-MB level, Killip clsass, MACE, age, and BMI. 560   Obesity and NT-ProBNP in AMI
Table 2 demonstrates that NT-proBNP was higher in men, in 
older patients, with elevated creatinine levels and with lower 
BMIs (p<0.001 in each case). Fig. 1 shows a box-plot of NT-
proBNP and Killip class. NT-proBNP was higher in the Killip 
class II, III, IV groups than in the Killip class I group (3,353± 
5,329 pg/mL vs. 1,174±2,240 pg/mL, p<0.001). Fig. 2 shows 
a box-plot of NT-proBNP in patients with (group II) and with-
out (group I) MACE. NT-proBNP was higher in group II than 
in group I (2,548±4,469 pg/mL vs. 1,530±3,088 pg/mL, p= 
0.001).
Obesity and N-terminal brain natriuretic peptide
Fig. 3 shows a box-plot of NT-proBNP and three obesity gr-
oups as categorized by BMI. The level of NT-proBNP de-
Table 1. Patient characteristics
Group I (n=2,478) Group II (n=258) p (CI=95%)
Mean age (years)* 065.6±12.4 067.1±12.2 0.015
Male (%)† 1,795 (72.4) 177 (68.6) 0.192
STEMI (%)† 1,538 (62.1) 165 (64.0) 0.552
Systolic BP (mmHg)
Diastolic BP (mmHg) 127.6±32.6 128.9±26.7 0.497
Heart rate (beats/min) 078.6±20.8 078.8±16.0 0.903
Past history (%)† 078.4±22.6 076.0±18.4 0.056
Smoking 1,522 (61.5) 162 (62.8) 0.684
Diabetes 0,627 (25.5) 084 (32.8) 0.011
Hypertension 1,104 (44.8) 115 (44.9) 0.963
Hyperlipidemia ,178 (7.2) 13 (5.0) 0.198
Prior myocardial infarction ,220 (8.9) 027 (10.5) 0.400
Laboratory findings
CK-MB (U/L)* 128.11±232.3  150.41±283.9 0.223
NT-proBNP (pg/mL)‡ 01,530±3,088 02,548±4,469 <0.001
Creatinine (mg/dL)* 01.01±0.29 01.00±0.25 0.244
Obesity†
Lean (BMI <23 kg/m
2) ,0924 (37.3) 104 (40.3) 0.454
Overweight (BMI 23.0-24.9 kg/m
2) 0,670 (27.0) 060 (23.3) 0.200
Obese (BMI >24.9 kg/m
2) 0,884 (35.7) 094 (36.4) 0.797
*By Chi-square test for dichotomous variables, †By Student t-test for continuous variables, ‡By Mann Whitney U test. MACE: major adverse 
cardiac events, CI: confidence interval, STEMI: ST-segment elevation myocardial infarction, BP: blood pressure, CK-MB: creatine kinase-
myocardial band isoenzyme, NT-proBNP: N-terminal brain natriuretic peptide, BMI: body mass index
Table 2. Independent variables of NT-proBNP in AMI patients
Variables
Unstandardized  
B coefficients
Standardized  
B coefficients
p*
(CI=95%)
Male sex -1078.019 -0.148 0.001
Killip class >I 1619.403 0.200 0.001
MACE 720.403 0.065 0.001
Age 29.134 0.111 0.001
BMI -117.950 -.0116 0.001
Past history (%)
Smoking -362.900 -0.054 0.015
Diabetes 241.141 0.032 0.068
Hypertension 98.700 0.015 0.420
Hyperlipidemia -6.178 0.000 0.978
Prior AMI 60.560 0.005 0.761
Laboratory findings
CK-MB (U/L) -0.664 -0.057 0.001
Creatinine (mg/dL) 3376.859 0.264 0.001
*By multiple linear regression model. NT-proBNP: N-terminal brain 
natriuretic peptide, CI: confidence interval, MACE: major adverse 
cardiac events, BMI: body mass index, AMI: acute myocardial in-
farction, CK-MB: creatine kinase-myocardial band isoenzyme
Fig. 1. Box-plot of NT-proBNP and Killip class. NT-proBNP was lo-
wer in the Killip class I group than in the Killip class II, III, IV groups 
(1,174±2,240 pg/mL vs. 3,353±5,329 pg/mL, p<0.001). NT-proB-
NP: N-terminal brain natriuretic peptide.
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creased as obesity increased (p=0.001). Table 3 shows the 
means NT-proBNP levels of each sub-group, divided by sex, obe-
sity degree, and MACE/non-MACE. A notable finding was 
that the mean NT-proBNP of male obese MACE patients was 
much lower than the mean NT-proBNP of female lean non-
MACE patients (1,134±2,310 vs. 3,121±4,349, p<0.001). Mul-
tivariate regression analysis identified BMI as an indepen-
dent negative correlate of NT-proBNP level (p<0.001) (Table 2). 
Prognostic value of N-terminal brain natriuretic
peptide related with obesity
For investigation of independent prognostic factors of AMI, 
we performed multivariate analysis and the results showed 
that DM, smoking, and NT-proBNP were independent prog-
nostic factors of AMI (Table 4). To focus on the influence of obe-
sity, we evaluated the prognostic value of NT-proBNP in each 
weight group (lean, overweight, obese) by binary logistic re-
gression (Table 5). NT-proBNP was still an independent prog-
nostic factor of AMI in obese patients (odds ratio=1.009, p= 
0.01) (Table 5).
Discussion
NT-proBNP is a natriuretic hormone released primarily from 
the heart ventricles. NT-proBNP is released from myocardial 
cells in response to volume expansion in HF. Therefore, NT-
proBNP has been used for diagnosis of symptomatic or asymp-
tomatic HF.
14) However, NT-proBNP is also thought to be re-
leased from ischemic myocardial cells due to an unknown me-
Fig. 3. Box-plot of NT-proBNP and three weight groups categorized 
by BMI. p=0.001 calculated by Kruskal-Wallis test. NT-proBNP: N-
terminal brain natriuretic peptide, BMI: body mass index.
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Fig. 2. Box-plot of NT-proBNP in patients with and without MACE. 
NT-proBNP was lower in patients without MACE (group I) than in 
patient with MACE (group II) (1,519±3,088 pg/mL vs. 2,548±4,469 
pg/mL, p=0.001). NT-proBNP: N-terminal brain natriuretic peptide, 
MACE: major adverse cardiac events.
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Table 3. The mean NT-proBNP levels of each sub-group divided by 
sex, obesity degree, and MACE (group II)/non-MACE (group I)
Group I mean  
NT-proBNP
Group II mean 
NT-proBNP
p
Male (n)
Lean  1,865±3,597 (540) 2,998±4,712 (55) 0.03
Overweight 1,135±2,765 (485) 1,268±1,943 (45) 0.75
Obese 0,770±1,705 (770) 1,134±2,310 (77) 0.09
Female (n)
Lean 3,121±4,349 (248) 4,643±5,177 (32) 0.07
Overweight 2,192±3,362 (171) 4,693±5,484 (23) 0.01
Obese 1,859±3,265 (264) 3,530±7,374 (26) 0.03
NT-proBNP: N-terminal brain natriuretic peptide, MACE: major 
adverse cardiac events
Table 4. Multivariative analysis of independent risk factors of 
MACE in all patients
Variables
Odds 
ratio
95% CI
p*
Lower Upper
Age (years) 1.009 0.996 1.002 0.162
Female sex 0.807 0.544 1.197 0.287
Systolic BP (mmHg) 0.995 0.986 1.004 0.261
Diastolic BP (mmHg 1.008 0.994 1.023 0.282
Heart rate (beats/min) 1.004 0.997 1.011 0.266
BMI 1.011 0.967 1.056 0.633
Killip class >I 1.142 0.826 1.578 0.422
STEMI 1.154 0.865 1.540 0.331
Patient’s history        
Hypertension 0.916 0.690 1.216 0.545
Prior AMI 1.213 0.783 1.878 0.387
Diabetes 1.344 1.004 1.800 0.047
Dyslipidemia 0.676 0.374 1.221 0.195
Smoking 1.428 1.003 2.033 0.048
Laboratory findings      
Creatinine (mg/dL) 0.979 0.563 1.702 0.940
NT-proBNP (pg/mL) 1.005 1.002 1.009 0.002
CK-MB (ng/mL) 0.635 0.990 1.006 0.635
*By binary logistic regression model. MACE: major adverse cardiac 
events, CI: confidence interval, BP: blood pressure, BMI: body mass 
index, STEMI: ST-segment elevation myocardial infarction, AMI: 
acute myocardial infarction, NT-proBNP: N-terminal brain natriure-
tic peptide, CK-MB: creatine kinase-myocardial band isoenzyme562   Obesity and NT-ProBNP in AMI
chanism. For this reason, many recent studies have demon-
strated the prognostic value of NT-proBNP in ACS patients
15)16) 
Because NT-proBNP levels rise rapidly after the onset of ACS 
symptoms, NT-proBNP can be used as a good independent 
prognostic indicator in the early evaluation of ACS patients.
17) 
However, there are many variables which influence NT-
proBNP levels. NT-proBNP is a biologically inert 76 amino 
acid N-terminal proBNP, produced by cleavage of the prohor-
mone (proBNP) from biologically active 32 amino acid BNP.
17) 
It is cleared by the kidney, with its plasma concentration 
therefore increased by renal failure.
9) The half-life of NT-pro-
BNP is about 120 minutes with normal kidney function.
18) 
We thus excluded renal insufficiency patients (Cr. >2.0 mg/
dL) in this study to minimize the influence of kidney func-
tion. The plasma concentrations of NT-proBNP are higher in 
older individuals and in women than in men.
8) According to 
our results, and as expected, NT-proBNP concentrations of 
women and older patients were significantly higher than those 
of young and male patients. Another influencing factor is 
HF. We excluded patients with previous HF history from the 
study population. The Killip classification categorizes AMI pa-
tients based upon the presence or absence of simple physical 
examination findings that suggest left ventricular (LV) dys-
function (HF).
19) Killip class I means no evidence of HF, with 
increasing Killip class number indicating increasing severity 
of HF. Our results showed significantly higher NT-proBNP 
levels with Killip class II-IV (HF) than with Killip class I (non-
HF). Finally, another factor strongly influencing NT-proB-
NP concentration is obesity. Many studies have shown that 
obese patients tend to have lower plasma NT-proBNP con-
centrations than nonobese patients.
20)21) One study recently an-
nounced that BNP levels cannot be used as a marker of LV 
wall stress in obese individuals.
22)
The aim of this study was to examine the influence of obe-
sity on NT-proBNP as a prognostic value in AMI patients of 
the KAMIR during 12 months of follow-up. We hypothesized 
that NT-proBNP in obese AMI patients could not be used as 
a prognostic factor of AMI due to the influence of obesity. Our 
results demonstrated that obese AMI patients have a lower 
level of NT-proBNP than lean or overweight AMI patients. The 
lowest mean NT-proBNP value was seen in male, obese, non-
MACE patients (Table 3). Notably, the mean NT-proBNP of 
male obese MACE patients was markedly lower than the mean 
NT-proBNP of female lean non-MACE patients. However, 
NT-proBNP still had an independent prognostic value for AMI 
among obese patients. This result suggests that obese AMI pa-
tients with higher NT-proBNP have worse prognoses. 
The mechanism of negative correlation of NT-proBNP and 
obesity is not yet known. Some authors have suggested that 
reduced secretion of natriuretic peptides from either dimin-
ished myocardial hormone release
23) or impaired synthesis
24) 
is the major cause of the inverse relationship between natri-
Table 5. Multivariative analysis of independent risk factors of MACE in each weight group
Variables
Lean Overweight Obese
p* OR p* OR p* OR
Age (years) 0.043 1.023 0.396 1.012 0.563 0.994
Female sex 0.116 0.625 0.866 0.931 0.846 1.074
Systolic BP (mmHg) 0.851 0.999 0.122 0.984 0.369 0.993
Diastolic BP (mmHg 0.989 1.000 0.143 1.025 0.295 1.013
Heart rate (beats/min) 0.587 1.003 0.135 1.010 0.988 1.000
BMI 0.336 0.940 0.333 0.780 0.714 1.018
Killip class >I 0.169 1.402 0.531 1.239 0.532 0.821
STEMI 0.910 0.974 0.872 0.950 0.040 1.669
Patient’s history
Hypertension 0.165 0.713 0.664 1.138 0.743 1.081
Prior AMI 0.124 1.664 0.894 0.926 0.988 0.994
Diabetes 0.546 1.166 0.014 2.096 0.236 1.332
Dyslipidemia 0.446 0.658 0.226 0.402 0.742 0.870
Smoking 0.038 1.827 0.095 1.852 0.794 0.925
Laboratory findings
Creatinine (mg/dL) 0.810 0.903 0.203 0.427 0.238 1.767
CK-MB (ng/mL) 0.518 1.004 0.954 1.001 0.061 0.987
NT-proBNP (pg/mL) 0.113 1.004 0.078 1.006 0.013 1.009
*By binary logistic regression model. MACE: major adverse cardiac events, OR: odds ratio, BP: blood pressure, BMI: body mass index, STE-
MI: ST-segment elevation myocardial infarction, AMI: acute myocardial infarction, CK-MB: creatine kinase-myocardial band isoenzyme, 
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uretic peptides and BMI.
There are several limitations to this study. First, our study 
was a multi-center prospective registry, and it was not a ran-
domized, controlled study. Thus, there was probably a selec-
tion bias when enrolling patients into both study groups. 
Second, we divided our groups according to BMI based on 
the World Health Organization cut-off values for overweight 
and obesity in Asians. This will inevitably make it difficult to 
directly compare our results with those of similar studies of non-
Asian patients. Third, the period of our study was relatively 
short as it was a comparison of MACE during 1 year clinical 
follow-up. Fourth, we were not able to include the follow-up 
NT-proBNP or BMI data. Another study demonstrated that 
early phase NT-proBNP (measured at 2-6 days after AMI) was 
a better prognostic factor than acute phase NT-proBNP (meas-
ured on arrival).
25) 
In conclusion, NT-proBNP is lower in obese AMI patients 
than in non-obese AMI patients, but NT-proBNP is still of 
independent prognostic value for obese AMI patients. Fur-
ther study will be necessary to investigate the complex rela-
tionships between MACE, BMI, sex, and NT-proBNP.
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